<DOC>
	<DOCNO>NCT01548287</DOCNO>
	<brief_summary>This study AZD5213 placebo give patient Mild Alzheimer 's Disease Mild Cognitive Impairment blind random assignment . The main study objective estimate relationship sleep duration versus dose 4 week treatment .</brief_summary>
	<brief_title>A Study Safety Tolerability AZD5213 Effect Sleep Patients With Alzheimer's/Cognitive Impairment</brief_title>
	<detailed_description>A Phase IIa Safety Tolerability Study Investigate Effect Sleep 3 Doses AZD5213 Placebo Patients Mild Alzheimer 's Disease Mild Cognitive Impairment During 4 Weeks Treatment , Designed Randomized , Double-Blind , Multi-Center , Parallel Group , Placebo-Controlled Study</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Patient study partner sign inform consent initiation studyrelated procedure . Clinical diagnosis Alzheimers ( AD ) mild cognitive impairment ( MCI ) disease . Single caregiver least 6 month prior Screening , capable accompany patient clinic visit need . The caregiver must either live visit patient least 10 hour per week , split multiple ( least 2 ) day , duration study . Single study partner , least several month prior Screening , capable accompany patient clinic visit need . The study partner must either live visit patient least 3 day per week duration study . A body mass index ( BMI=weight/height2 ) 18 kg/m2 32 kg/m2 . Significant neurological disease dementia AD MCI . Current episode symptom major depressive disorder major psychiatric disorder . History selfreported sleep duration le 4 hour per night le 4 hour average total sleep time per night Baseline PSG assessment . History present symptom sleep disorder sleep apnea . History cancer last 5 year . Use antiAD drug ( include offlabel drug herbal medication ) exception donepezil , memantine , and/or rivastigmine transdermal system , monotherapy combination follow condition : treatment donepezil ( 5 mg 10 mg daily ) , memantine , and/or rivastigmine transdermal system combination regimens least 3 month stable dose ( ) last 2 month prior randomization allow .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Mild Cognitive Impairment</keyword>
	<keyword>Mild Alzheimer 's disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>